Business Description
Founded in 2019 and headquartered in Subiaco, Australia, Invex Therapeutics is working to bring new medical options to patients suffering from serious brain and nervous system disorders. The company's primary focus is Exenatide, a drug targeting conditions caused by elevated pressure within the skull, including idiopathic intracranial hypertension, acute stroke, and traumatic brain injury, which has already completed Phase III clinical trials. Invex works alongside partner Tessara Therapeutics to advance its research goals.
